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Cost-EffECtivENEss ANAlysis of NEo-AdjuvANt PErtuzumAb thErAPy 
iN WomEN With loCAlly AdvANCEd, iNflAmmAtory, or EArly  
hEr2-PositivE brEAst CANCEr iN itAly
Pradelli L1, Bellone M1, Era S2, Campagnoli E2
1AdRes Srl, Torino, Italy, 2Roche Spa, Monza (MB), Italy
Objectives: The aim of this study was to evaluate the cost-effectiveness of 
pertuzumab in combination with trastuzumab and docetaxel as neo-adjuvant 
treatment for locally advanced, inflammatory, or early stage breast cancers that 
overexpress Human Epidermal growth factor Receptor 2 (HER2), from the Italian 
National Health System (SSN) perspective. MethOds: A six state Markov model 
was used to estimate outcomes and costs over a 50-year time horizon. Patients 
were assumed to receive standard neo-adjuvant therapy containing trastuzumab 
and docetaxel or the same regimen plus pertuzumab. Transition probabilities to 
progressive disease and death were based on total pathological complete response 
(pCR) rates observed in the NeoSphere study. A second analysis was carried out 
in which progression-free survival (PFS) was directly modelled on observed 
data. Expected survival was adjusted by utility weights for health states derived 
from literature. Direct medical unit costs were collected from official and pub-
lished Italian sources. Costs and health gains were discounted at an annual 3% 
rate. Probabilistic sensitivity analysis (PSA) was carried out to evaluate uncer-
tainty. Results: Pertuzumab combination was associated with increased QALYs 
and costs relative to standard neo-adjuvant regimen. Acquisition drug cost of 
pertuzumab was the primary contributor to the difference in costs, partially off-
set through the prevention of relapse and worsening. The estimated ICERs range 
between € 3,000 and € 19,000 per QALY. In PSA, pertuzumab combination has very 
high probability of being cost effective relative to standard regimen for a WTP 
threshold of € 40,000 per QALY gained. cOnclusiOns: Breast cancer with HER2 
overexpression is associated with increased tumour aggressiveness, higher rates 
of recurrence and mortality. In the neo-adjuvant setting, pertuzumab in combina-
tion with trastuzumab and docetaxel is expected to be more effective (increased 
probability to reach higher pCR rate and longer PFS) than standard regimen, at a 
favourable cost per QALY gained.
PCN140
A Cost utility ANAlysis of CEtuximAb for 1st-liNE trEAtmENt of 
rAs Wild-tyPE mEtAstAtiC ColorECtAl CANCEr: A summAry of thE 
submissioN to All WAlEs mEdiCiNEs strAtEgy grouP (AWmsg)
Hnoosh A1, Harty GT2, Sullivan L2, Byrne B2, von Honhorst P3
1Merck Serono Ltd., FELTHAM, UK, 2Merck Serono, London, UK, 3Merck KGaA, Darmstadt, 
Germany
Objectives: Colorectal cancer is the third most common cancer in Wales, with 2444 
new cases reported in 2012. Incidence increased by 28.5% between 2002 and 2012. 
While survival rates in colorectal cancer are improving globally, the UK continues to 
lag behind other major economies. Recent evidence demonstrates that cetuximab 
can result in significant life extension when added to chemotherapy as a first line 
treatment of RAS wild type metastatic colorectal cancer. At present, cetuximab is 
funded in Wales mainly through Individual Patient Treatment Requests which are 
increasing in number due to the rising demand from both patients and physicians. 
An evidence submission was submitted to AWMSG to highlight this clinical benefit 
and assess the cost effectiveness of cetuximab. MethOds: An economic model 
was developed to assess the cost effectiveness of cetuximab in the management 
of unresectable RAS wt metastatic colorectal cancer in comparison to comparators 
available in the Welsh NHS; FOLFOX, FOLFIRI, or CAPOX alone. This includes a small 
population of patients with metastases confined to the liver who may subsequently 
be eligible for curative resection after treatment with cetuximab plus chemotherapy. 
The time horizon is 10 years and the discount rate applied to both outcomes and 
costs is 3.5%. Cetuximab Welsh Patient Access Scheme (WPAS) price was used in 
all analyses and the dose was set to fortnightly dosing as typically prescribed in 
Wales. Results: Economic analyses estimated an incremental cost effectiveness 
ratio of £29,512 per QALY gained for cetuximab + FOLFOX compared to FOLFOX 
alone and £35,731 per QALY gained for cetuximab + FOLFIRI compared to FOLFIRI 
alone. cOnclusiOns: These analyses demonstrate that cetuximab is a cost effec-
tive treatment and a good use of NHS Wales resources through stratification of 
RAS wild type patients who are likely to respond to treatment and offer patients a 
life-extending treatment option.
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thE Cost EffECtivENEss of idElAlisib iN ChroNiC lymPhoCytiC 
lEukAEmiA iN ENglANd ANd WAlEs
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bAckgROund: In September 2014 the European Commission granted market-
ing authorisation for idelalisib with rituximab (I+R) for the treatment of chronic 
lymphocytic leukaemia (CLL) in previously treated patients and treatment-naïve 
patients with a 17p deletion or TP53mutation. Objectives: This study evaluated 
the cost effectiveness of I+R in previously-treated patients according to their eli-
gibility for chemo-immunotherapy in England and Wales. MethOds: A 5-state 
Markov model was constructed from a National Health Service (NHS) perspective 
over a lifetime horizon. Study 116 contained 220 patients for whom chemo-immu-
notherapy was unsuitable owing to poor previous response to such treatment, 
the presence of 17p deletion or TP53mutation, or their fitness, randomised 1:1 
to I+R (intervention) or rituximab with placebo (comparator). Intervention-arm 
data from Study 116 were used to inform the effectiveness of I+R in terms of 
response, time on treatment, progression-free and overall survival. Comparator-
arm data from Study 116 were used to inform the effectiveness of (i) rituximab 
monotherapy, and using further assumptions, (ii) ofatumumab monotherapy and 
Objectives: The objective of this study was to estimate Incremental Cost-
Effectiveness Ratio(ICER) of utilizing eribulin against Treatment of Physician’s 
Choice (TPC) for third line treatment of Metastatic Breast Cancer(MBC) in 
Taiwan. MethOds: Efficacy and safety data was obtained from a multicentre phase 
III clinical trial (EMBRACE) comparing eribulin against TPC. A five-year partitioned 
survival cost-effectiveness analysis(CEA) with a Quality-adjusted Time Without 
Symptoms and Toxicity(Q-TWiST) as the effectiveness measure was developed. 
Costs included in the model were drugs & administration, post-treatment resource 
use, toxicity management and indirect treatment costs. Cost effectiveness was eval-
uated using the Gamma distribution for Overall Survival(OS), Weibull for Progression 
Free Survival(PFS), response duration and, toxicity time. Health state utilities were 
applied to each component and aggregated. In base-case analysis, 3% discount-
ing was applied for both benefits and costs. Deterministic sensitivity analysis was 
used to evaluate sensitivity of the key variables. Results: OS based on Gamma 
extrapolation was 17.26 months in eribulin group versus 14.39 months in TPC group 
for a difference of 2.87 months. Mean time without progressive disease was 4.68 
months for eribulin and 3.96 months for TPC for a difference of 0.72 months. The 
Quality Adjusted Life Years were 0.83 in the eribulin group compared to 0.70 in TPC 
group for a mean incremental improvement of 0.13 years. Treatment costs were 
NTD 351,875 for eribulin and NTD 113,552 for TPC for a difference of NTD 238,323. 
In base-case analysis, the ICER with discounting was NTD 1,823,482. Survival time 
was most sensitive variables on the ICER in this CEA. cOnclusiOns: With an ICER 
of NTD 1,823,482 compared to TPC, eribulin was found to be cost-effective in third 
and later line MBC population in Taiwan. Given the limited number of effective 
therapeutic options available to these patients, eribulin represents a valid option 
for optimizing treatment pathways.
PCN137
AflibErCEPt iN CombiNAtioN With folfiri iN PAtiENts With mEtAstAtiC 
ColorECtAl CANCEr: Cost-EffECtivENEss bAsEd oN vElour bEst 
EffiCACy subgrouP Post-hoC ANAlysis
Echave M1, Oyagüez I1, Lamas MJ2, Rubio M3, Subirà R3
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Complexo Hospitalario de 
Santiago de Compostela, Santiago de Compostela, Spain, 3Sanofi, Barcelona, Spain
Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept 
in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer 
(mCRC) in Best Efficacy Subgroup (BES) patients previously treated with oxaliplatino 
compared to FOLFIRI. MethOds: A post-hoc analysis of the VELOUR clinical trial 
revealed an improvement of aflibercept efficacy in a specific subgroup. BES was com-
posed by patients with performance status (PS) 0 with any number of metastatic sites 
or PS 1 with < 2 metastatic sites, exclusive of adjuvant fast relapsers. A Markov model 
with 3 health states (stable disease, progression and death) was used to estimate 
lifetime costs and outcomes (2-weeks cycle duration). Transition from stable disease 
to progression implied the interruption of second-line treatment and administra-
tion of a third-line chemotherapy (72%) or best supportive care (28%). According to 
the National Health System (NHS) perspective only direct costs were considered. 
Cost estimation (€ , 2015) included pharmaceutical and administration cost, adverse 
event management and hospital and medical visits consumption. Ex-factory price 
with mandatory deduction was applied for drug cost estimation. Costs and outcomes 
were 3% annually discounted. Sensitivity analyses (SA) were performed. Results: 
Administration of aflibercept + FOLFIRI as second-line treatment on BES was more 
effective than FOLFIRI, yielding 1.92 LYG (23 life-months gained) compared to 1.55 
LYG (18.6 months). Aflibercept + FOLFIRI accounted a total cost of € 40,449, compared 
to € 25,698 estimated for FOLFIRI. The incremental cost-effectiveness analysis pro-
vided a € 33,373/LYG ratio for aflibercept in combination with FOLFIRI versus FOLFIRI 
for BES. SA results confirmed the model robustness. cOnclusiOns: According to 
a post-hoc analysis, aflibercept in combination with FOLFIRI could increase overall 
survival versus FOLFIRI on BES. Aflibercept + FOLFIRI could be an efficient strategy for 
second-line treatment in specific mCRC patients for the Spanish NHS.
PCN138
Cost-EffECtivENEss of CArdioProtECtivE EffECt of dExrAzoxANE 
(CArdioxANE®) iN AdvANCEd/mEtAstAtiC brEAst CANCEr PAtiENts 
trEAtEd With ANthrACyCliNE-bAsEd ChEmothErAPy iN méxiCo
Paladio-Hernández JÁ1, Martínez-Morales J2
1Independent Consultant, Cuautitlán Izcalli, Mexico, 2UACH, Hidalgo del Parral, Mexico
Objectives: The problem of anthracycline-induced clinical heart failure is an 
important public health concern as it may not be seen for many years and remains 
a life-long threat. We performed a cost-effectiveness analysis of the cardioprotec-
tive effect of Dexrazoxane in advanced/metastatic breast cancer patients treated 
with anthracycline-based chemotherapy in México. MethOds: A decision tree 
model was developed in order to compare dexrazoxane with no treating. The time 
horizon was one year. The main data for dexrazoxane efficacy (surgery require-
ment and functional loss) was obtained from two open label non-comparative 
studies. Main costs taken into account were the drug costs, administration and 
monitoring and surgical costs. Results: Dexrazoxane may lead to important 
savings for the Mexican public health system when it is compared to no treat-
ing. The results derived from the model indicate that Dexrazoxane is associated 
with less cardiac events (39% versus 13%, P < 0.001) and a lower and less severe 
incidence of congestive heart failure (11% versus 1%, P < 0.05) which represent a 
saving of 200,000 USD per patient treated. Tumor response rate was unaffected 
by dexrazoxane therapy. The frequency of adverse events was similar between 
groups and there were no significant between-group differences in the number 
of dose modifications/interruptions. cOnclusiOns: Dexrazoxane is a dominant 
alternative vs no treating since it significantly reduced the occurrence and severity 
of anthracycline-induced cardiotoxicity in patients at increased risk of cardiac 
dysfunction due to previous anthracycline treatment without compromising 
the antitumor efficacy of the chemotherapeutic regimen at a lower cost than no 
treating
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Objectives: Regorafenib is indicated in the treatment of locally advanced, non-
resectable gastrointestinal stromal tumors (GIST) that did not respond to prior 
imatinib mesylate and sunitinib malate. The objective of this study is to evaluate 
the cost-effectiveness of regorafenib compared to standard care, since no other third 
line treatment is available, in metastatic/inoperable GISTs in Turkey. MethOds: A 
Markov model taking transitions of patients between three health states of “progres-
sion-free”, “progressed” or “dead” was adapted to Turkish settings. Clinical transition 
inputs between health states and safety data were mainly derived from GRID study. 
Economic inputs were based on the experts’ opinion addressing local treatments, 
routine monitoring and adverse event management algorithms. The incremental 
cost-effectiveness ratios (ICER) were calculated per quality adjusted life years (QALY) 
gained. Analyses were conducted from the Turkish Payer Social Security Institution 
perspective. All costs were calculated in Turkish Liras (TL). The cost effectiveness 
(CE) threshold defined by World Health Organization (WHO) for developing countries 
as ICER 1-3 fold of annual income per capita was calculated based on the Turkish 
2014 annual income per capita of 10,404.00 USD and converted to TL using TL/USD 
currency rate of 2.28 (end of 2014). Results: Total costs associated with regorafenib 
and standard care are 22,902 and 1,692 TL, respectively. On the other hand, QALYs 
gained with regorafenib (2.714) was almost twice compared to standard care (1.402), 
with an ICER of 16,481 TL/year. This additional cost of treatment is below the lower 
margin of CE threshold that was 23,721.00 TL. cOnclusiOns: Regorafenib is a cost-
effective treatment option in metastatic/inoperable GISTs in Turkey. Compared to 
standard care, the additional cost of treatment is below the CE threshold.
PCN145
Cost-EffECtivENEss of suNitiNib As sECoNd-liNE trEAtmENt for 
gAstroiNtEstiNAl stromAl tumor(gist) iN ChiNA
Ren H1, Zhang J2, Dong P3
1Pfizer China, Shanghai, China, 2Southern Medical University, Guangzhou, China, 3Pfizer 
Investment Co., Ltd., Beijing, China
Objectives: Sunitinib is a multitargeted receptor tyrosine kinase inhibitor that has 
demonstrated its efficacy in treating Gastrointestinal stromal tumor (GIST) patients 
who are no longer responded to imatinib 400mg/day. The purpose of this study is to 
evaluate the cost-effectiveness of sunitinib as a second-line treatment in patients 
with advanced GISTs in China from a third party payer’s perspective. MethOds: 
A Markov model was developed to simulate disease progression and to determine 
cost and effectiveness outcomes over a 5-year time horizon. The different second-
line treatment arms compared were sunitinib 50 mg/day (4 weeks on and 2 weeks 
off), imatinib 600 mg/day, imatinib 800 mg/day, and best supportive care (BSC). The 
probabilities of state transitions and utilities were obtained from previous published 
trials. Resource use and costs data were obtained from previous studies and public 
sources. A 3.5% annual discount rate after the first year was applied to both costs 
and outcomes. The incremental cost-effectiveness ratios (ICER) between treatment 
with sunitinib vs. other treatment options were calculated. Results: In the base 
case, treatment with sunitinib vs. imatinib 600 mg resulted in 0.744 PFLY gained, 
0.423 LY gained and 0.398 QALYs gained at an incremental cost of RMB14,750. The 
ICER was RMB37,023 per QALY gained. Treatment with sunitinib was dominant 
compared with imatinib 800 mg, with lower costs and higher QALYs . Treatment 
with sunitinib vs BSC resulted in patients’ benefits of 0.257 PFLY gained, 1.357 LY 
gained and 0.836 QALYs gained at an incremental cost of RMB106,889. The ICER 
was RMB127,801 per QALY gained. cOnclusiOns: Among patients with advanced 
GISTs who have failed imatinib 400mg/day as the first-line treatment, sunitinib 
provides greater clinical benefit than high-dose imatinib or BSC. In the Chinese 
setting, sunitinib is estimated to be either cost-saving or cost-effective compared 
with imatinib 800 mg, imatinib 600mg or BSC.
PCN146
Cost-EffECtivENEss of CEritiNib iN thE trEAtmENt of PrEviously 
trEAtEd ANAPlAstiC lymPhomA kiNAsE-PositivE (Alk+) NoN-smAll CEll 
luNg CANCEr iN thE uNitEd kiNgdom
Zhou Z1, Zhang J2, Fan L3, Zhang C3, Xie J4
1Analysis Group Inc., New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA, 3Analysis Group, Inc., Boston, MA, USA, 4Analysis Group, Inc., New York, NY, USA
Objectives: To assess the cost-effectiveness of ceritinib versus other therapies in 
the treatment of anaplastic lymphoma kinase-positive (ALK+) non-small cell lung 
cancer (NSCLC) from the UK National Health Service (NHS) and Personal Social 
Service (PSS) perspective. MethOds: A partitioned survival model with three health 
states (progression-free, progressive, and death) was developed to compare ceri-
tinib versus other treatments in patients with ALK+ NSCLC who were previously 
treated with chemotherapy (post-CT), or with an ALK inhibitor, regardless of prior 
chemotherapy (post-ALKi). The comparator arms included crizotinib, docetaxel, and 
pemetrexed in the post-CT population and best supportive care (BSC), docetaxel, 
and pemetrexed in the post-ALKi population. Progression-free survival and overall 
survival for ceritinib were estimated using the ASCEND-1 (NCT01283516), ASCEND-2 
(NCT01685060), and ASCEND-3 (NCT01685138) trial data. Parametric models were 
used to extrapolate outcomes beyond the trial period. Survival data for compara-
tors were obtained from published clinical trials. Drug acquisition, administration, 
medical and adverse event (AE) costs were obtained from publicly available data-
bases. Utilities for health states and disutilities for AEs based on EQ-5D were derived 
from literature. Incremental costs per quality-adjusted life year (QALY) gained were 
estimated comparing ceritinib vs. each comparator. Univariate and probabilistic 
sensitivity analyses were performed. Results: Over 10 years, ceritinib was associ-
ated with 2.69 QALYs and total direct costs of £80,445 for post-CT population. The 
incremental cost per QALY was £30,536 comparing ceritinib vs. crizotinib, £44,847 vs. 
docetaxel, and £38,966 vs. pemetrexed. Among post-ALKi population, the QALY and 
total direct costs for ceritinib were 0.94 and £45,712 respectively. The incremental 
cost per QALY was £48,808 comparing ceritinib vs. BSC, £57,660 vs. docetaxel, and 
£40,145 vs. pemetrexed. Sensitivity analysis results were consistent with the base-
case findings. cOnclusiOns: Based on the willingness-to-pay threshold for end-
(iii) best supportive care (BSC). To compare I+R to steroids with rituximab (an 
alternative treatment for the patient group in Study 116) and to make exploratory 
comparisons to chemo-immunotherapies, curve fits to systematically-identified 
comparator trial data were made using a common-shape approach and adjust-
ment for prognostic factors. Utility data and drug, medical resource, adverse event 
and terminal care costs were obtained from Study 116 EQ-5D surveys, published 
sources and clinical input. Results: Compared to (i) rituximab monotherapy, (ii) 
ofatumumab monotherapy and (iii) BSC, in patients ineligible for chemo-immu-
notherapy, the base case ICERs for I+R were (i) £21,224, (ii) £9,116 and (iii) £28,015 
per QALY gained, respectively and inclusive of a simple price discount. Further 
comparisons provided ICERs ranging from £20,431 to £34,603. cOnclusiOns: 
I+R was shown to be cost effective in previously-treated patients ineligible for 
chemo-immunotherapy.
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Cost-EffECtivENEss of ofAtumumAb Plus ChlorAmbuCil iN first-liNE 
ChroNiC lymPhoCytiC lEukEmiA iN thE uNitEd kiNgdom
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Objectives: To evaluate the cost-effectiveness of ofatumumab plus chlorambucil 
(OChl) versus chlorambucil (Chl) for the first-line treatment of chronic lympho-
cytic leukemia (CLL) in patients not eligible for fludarabine-based therapy from the 
United Kingdom health care payer perspective. MethOds: A semi-Markov decision 
model was developed with a lifetime time horizon of 25 years and a 3-month cycle 
length. The COMPLEMENT-1 trial provided estimates of overall response rates (ORR), 
progression-free survival (PFS), overall survival (OS), safety data, and preprogression 
utility weights (EQ-5D). The number of patients in the “preprogression,” “progres-
sive disease,” and “dead” health states at the end of each cycle was determined by 
parametric survival functions for PFS and OS. Long-term predictions for OS were 
guided by external data; the treatment effect observed in the trial was assumed not 
to continue beyond trial follow-up. Data from published literature and UK treatment 
practices and patterns were used to inform costs and utility in the postprogression 
health states. Incremental lifetime costs and quality-adjusted life-years (QALYs) 
were calculated. Results: The base-case incremental cost-effectiveness ratio (ICER) 
was £32,950 per QALY gained, with incremental discounted costs and QALYs of 
£10,492 and 0.32, respectively. Discount rate was 3.5% for both cost and outcomes. 
The probability of cost-effectiveness at a willingness-to-pay threshold of £30,000 
per QALY was 43%. Univariate sensitivity analyses indicated that the proportion of 
patients who received active therapy after progression following first-line treatment 
(responders, active second-line treatment) had the largest influence on the ICER. 
However, none of the variables considered generated an ICER exceeding £38,000 
per QALY gained. cOnclusiOns: The improved ORR, PFS, and OS for OChl com-
pared with Chl translated to improved long-term health outcomes in the base-case 
analysis. The results were robust in a wide range of sensitivity analyses and did not 
exceed £38,000/QALY.
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A sCotlANd bAsEd Cost-EffECtivENEss ANAlysis of idElAlisib 
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Adults With ChroNiC lymPhoCytiC lEukAEmiA Cll)
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Objectives: Idelalisib/ rituximab (IR) is licenced for the treatment of adults 
with CLL who either have received at least one previous therapy and as first 
line treatment for patients with del17p/TP53 mutations. Prior to the availability 
of IR, individuals in these patient groups received best supportive care (BSC). 
The clinical efficacy of the IR in these patient groups was demonstrated in a 
Phase III RCT (‘study 116’). The cost-effectiveness of IR in this patient group is 
unknown. MethOds: A response stratified partitioned survival model (overall 
survival - OS, progression free survival - PFS) was developed to estimate the life-
time costs and benefits associated with IR and BSC for a Scottish NHS perspective 
using a lifetime horizon and monthly cycles. OS, PFS, overall response (OR) and 
resource use data was taken directly from study 116. Information from study 
116 was used as far as possible for patients with del17p / TP53 mutations, with 
expert opinion used where necessary. Utility scores were taken from published 
sources. Unit/drug costs were taken from national databases and discounted at 
3.5% p.a. Probabilistic and deterministic sensitivity analyses were conducted to 
estimate the confidence around the results. Outcomes are reported via incremen-
tal cost-effectiveness ratios (ICER, benefit expressed as QALYs). Results: For all 
patients the ICER for all patients was £32,180/ QALY (Δ QALYs:2.04, Δ Costs:£64,629). 
In patients with del 17p/TP53 mutations the ICER was £19,040/QALY (Δ QALYs:4.39, 
Δ Costs:£83,636). The results were sensitive to changes in OR rates and utility val-
ues. In particular, the ICERs fell below £30,000/QALY if utility values from previ-
ous UK HTAs of treatments for CLL were used. The ICERs were robust to changes 
in adverse event rates/costs and alterations to background resource use pat-
terns. cOnclusiOns: IR is likely to be a cost-effective intervention in all CLL 
patients for which it has achieved European marketing approval.
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